Top

Published in:

Open Access 01-12-2024 | Salmeterol | Matters Arising

Bronchodilator reversibility testing in morbidly obese non-smokers: a comparative study– few concerns

Authors: Divya Balan, Manish R Shetty, Manu K Mohan

Published in: BMC Pulmonary Medicine | Issue 1/2024

Abstract

This is a letter in response to an article by Ahmed et al., which concluded that in comparison to salbutamol, Fluticasone/salmeterol combination increases FEV₁, FEV₁% of predicted, and FEV₁/FVC ratio, however it did not offer novel insights, as both agents met the 12%- and 200-mL reversibility benchmarks and Concerns about incorporating a combination medication that includes an inhaled corticosteroid, inhaled corticosteroids are not typically associated with bronchodilation.

Ahmed MI, Ahmed RI, Osama H, et al. Bronchodilator reversibility testing in morbidly obese non-smokers: fluticasone/salmeterol efficacy versus salbutamol bronchodilator. BMC Pulm Med. 2023;23(1):381. https://doi.org/10.1186/s12890-023-02682-3CrossRefPubMedPubMedCentral

Barnes PJ. Inhaled corticosteroids. Pharmaceuticals (Basel). 2010;3(3):514–40. https://doi.org/10.3390/ph3030514CrossRefPubMed

Liang TZ, Chao JH. Inhaled corticosteroids. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470556/

Ejiofor S, Turner AM. Pharmacotherapies for COPD. Clin Med Insights Circ Respir Pulm Med. 2013;7. https://doi.org/10.4137/CCRPM.S7211

Title: Bronchodilator reversibility testing in morbidly obese non-smokers: a comparative study– few concerns
Authors: Divya Balan
Manish R Shetty
Manu K Mohan
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Salmeterol
Salbutamol
Fluticasone
Published in: BMC Pulmonary Medicine / Issue 1/2024
Electronic ISSN: 1471-2466
DOI: https://doi.org/10.1186/s12890-024-02951-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Implications of GCLC in prognosis and immunity of lung adenocarcinoma and multi-omics regulation mechanisms

Study on predictive models for swallowing risk in patients with AECOPD

Long-term pulmonary outcomes of young adults born prematurely: a Polish prospective cohort study PREMATURITAS 20

The value of dynamic FDG PET/CT in the differential diagnosis of lung cancer and predicting EGFR mutations

Age at menarche and idiopathic pulmonary fibrosis: a two-sample mendelian randomization study

Potential for recovery after extremely prolonged VV-ECMO support in well-selected severe COVID-19 patients: a retrospective cohort study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials